{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T17:01:52Z","timestamp":1765040512001},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,6,21]],"date-time":"2014-06-21T00:00:00Z","timestamp":1403308800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Pharm. Res."],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s12272-014-0419-0","type":"journal-article","created":{"date-parts":[[2014,6,20]],"date-time":"2014-06-20T00:40:35Z","timestamp":1403224835000},"page":"957-966","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Clinical implication of SGLT2 inhibitors in type 2 diabetes"],"prefix":"10.1007","volume":"37","author":[{"given":"Go Woon","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Hyun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,21]]},"reference":[{"key":"419_CR1","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.2174\/0929867043364360","volume":"11","author":"T Asano","year":"2004","unstructured":"Asano, T., T. Ogihara, H. Katagiri, H. Sakoda, H. Ono, M. Fujishiro, M. Anai, H. Kurihara, and Y. Uchijima. 2004. Glucose transporter and Na+\/glucose cotransporter as molecular targets of anti-diabetic drugs. Current Medicinal Chemistry 11: 2717\u20132724.","journal-title":"Current Medicinal Chemistry"},{"key":"419_CR2","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","volume":"375","author":"CJ Bailey","year":"2010","unstructured":"Bailey, C.J., J.L. Gross, A. Pieters, A. Bastien, and J.F. List. 2010. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, double-blind, placebo-controlled trial. Lancet 375: 2223\u20132233.","journal-title":"Lancet"},{"key":"419_CR3","first-page":"CD4654","volume":"2","author":"C Black","year":"2007","unstructured":"Black, C., P. Donnelly, L. Mcintyre, P.L. Royle, J.P. Shepherd, and S. Thomas. 2007. Meglitinide analogues for type 2 diabetes mellitus. The Cochrane Database of Systematic Reviews 2: CD4654.","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"419_CR4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3810\/hp.2013.04.1020","volume":"41","author":"B Bode","year":"1995","unstructured":"Bode, B., K. Stenl\u00f6f, D. Sullivan, A. Fung, and K. Usiskin. 1995. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: A randomized trial. Hospital Practice 41: 72\u201384.","journal-title":"Hospital Practice"},{"key":"419_CR5","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"Bolinder, J., O. Ljunggren, J. Kullberg, L. Johansson, J. Wildding, A.M. Langkilde, J. Sugg, and S. Parikh. 2012. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. The Journal of Clinical Endoclinology & Metabolism 97: 1020\u20131031.","journal-title":"The Journal of Clinical Endoclinology & Metabolism"},{"key":"419_CR6","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S1262-3636(08)73395-0","volume":"34","author":"R Burcelin","year":"2008","unstructured":"Burcelin, R., C. Knauf, and P.D. Cani. 2008. Pancreatic alphacell dysfunction in diabetes. Diabetes Metabolism 34: S49\u2013S55.","journal-title":"Diabetes Metabolism"},{"key":"419_CR7","first-page":"E78","volume":"276","author":"E Cersosimo","year":"1999","unstructured":"Cersosimo, E., P. Garlick, and J. Ferretti. 1999. Insulin regulation of renal glucose metabolism in humans. American Journal of Physiology 276: E78\u2013E84.","journal-title":"American Journal of Physiology"},{"key":"419_CR8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","volume":"9","author":"EC Chao","year":"2010","unstructured":"Chao, E.C., and R.R. Henry. 2010. SGLT2 inhibition: A novel strategy for diabetes treatment. Nature Reviews Drug Discovery 9: 551\u2013559.","journal-title":"Nature Reviews Drug Discovery"},{"key":"419_CR9","doi-asserted-by":"crossref","first-page":"4645","DOI":"10.1210\/jc.2009-1412","volume":"94","author":"MS Copper","year":"2009","unstructured":"Copper, M.S., and P.M. Stewart. 2009. 11\u03b2-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus\u2013pituitary\u2013adrenal axis, metabolic syndrome, and inflammation. The Journal of Clinical Endocrinology and Metabolism 94: 4645\u20134654.","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"419_CR10","first-page":"595","volume":"13","author":"G Croasdell","year":"2010","unstructured":"Croasdell, G. 2010. American Diabetes Association: 70th scientific sessions: Research on novel therapeutics: Part 1. The Investigational Dugs Journal 13: 595\u2013597.","journal-title":"The Investigational Dugs Journal"},{"key":"419_CR11","first-page":"393","volume":"364","author":"Diabetes Prevention Program Research Group","year":"2002","unstructured":"Diabetes Prevention Program Research Group. 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine 364: 393\u2013403.","journal-title":"The New England Journal of Medicine"},{"key":"419_CR12","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker, D.J., and M.A. Nauck. 2006. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696\u20131705.","journal-title":"Lancet"},{"key":"419_CR13","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1016\/j.bmcl.2004.07.082","volume":"14","author":"J Dudash Jr","year":"2004","unstructured":"Dudash Jr, J., X. Zhang, R.E. Zeck, S.G. Johnson, G.G. Cox, B.R. Conway, P.J. Rybczynski, and K.T. Demarest. 2004. Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporters 2 (SGLT2) inhibitors. Bioorganic & Medicinal Chemistry Letters 14: 5121\u20135125.","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"419_CR14","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2741\/3301","volume":"14","author":"DS Edgerton","year":"2009","unstructured":"Edgerton, D.S., K.M. Johnson, and A.D. Cherrington. 2009. Current strategies for the inhibition of hepatic glucose production in type 2 diabetes. Frontiers in Bioscience 14: 1169\u20131181.","journal-title":"Frontiers in Bioscience"},{"key":"419_CR15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/dmrr.532","volume":"21","author":"RRL Ehrenkranz","year":"2005","unstructured":"Ehrenkranz, R.R.L., N.G. Lewis, C.R. Kahn, and J. Roth. 2005. Phlorizin: A review. Diabetes Metabolism Research Reviews 21: 31\u201338.","journal-title":"Diabetes Metabolism Research Reviews"},{"key":"419_CR16","unstructured":"FDA. 2011. FDA briefing document. NDA 202293. Dapagliflozin tablets, 5 and 10\u00a0mg. Sponsor: Bristol-Myers Squibb. Advisory Committee Meeting."},{"key":"419_CR17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/dom.12273","volume":"16","author":"T Forst","year":"2014","unstructured":"Forst, T., R. Guthrie, R. Goldenberg, J. Yee, U. Vijapurkar, G. Meininger, and P. Stein. 2014. Efficacy and safety of canagliflozin over 52\u00a0weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes, Obesity & Metabolism 16: 467\u2013477.","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"419_CR18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/jpet.108.140210","volume":"327","author":"Y Fujimori","year":"2008","unstructured":"Fujimori, Y., K. Katsuno, I. Nakashima, Y. Ishikawa-Takemura, H. Fujikura, and M. Isaji. 2008. Remogliflozin etabonate, in a novel category of selective low-affinity\/high-capacity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. The Journal of Pharmacology and Experimental Therapeutics 327: 268\u2013276.","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"419_CR19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","volume":"14","author":"R Grempler","year":"2012","unstructured":"Grempler, R., L. Thomas, M. Eckhardt, F. Himmelsbach, A. Sauer, D.E. Sharp, R.A. Bakker, M. Mark, T. Klein, and P. Eickelmann. 2012. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors. Diabetes, Obesity & Metabolism 14: 83\u201390.","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"419_CR20","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.metabol.2004.01.018","volume":"53","author":"SM Gustavson","year":"2004","unstructured":"Gustavson, S.M., et al. 2004. Effects of hyperglycemia, glucagon, and epinephrine on renal glucose release in the conscious dog. Metabolism 53: 933\u2013941.","journal-title":"Metabolism"},{"key":"419_CR21","doi-asserted-by":"crossref","first-page":"10641","DOI":"10.1021\/jf0722598","volume":"55","author":"GC Han","year":"2007","unstructured":"Han, G.C., S.K. Ko, J.H. Sung, and S.H. Chung. 2007. Compound K enhances insulin secretion with beneficial metabolic effects in db\/db mice. Journal of Agricultural and Food Chemistry 55: 10641\u201310648.","journal-title":"Journal of Agricultural and Food Chemistry"},{"key":"419_CR22","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2337\/db07-1472","volume":"57","author":"S Han","year":"2008","unstructured":"Han, S., D.L. Hagan, J.R. Taylor, L. Xin, W. Meng, S.A. Biller, J.R. Wetterau, W.N. Washburn, and J.M. Whaley. 2008. Dapagliflozin: A selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57: 1723\u20131729.","journal-title":"Diabetes"},{"key":"419_CR23","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1152\/physrev.1994.74.4.993","volume":"74","author":"MA Hediger","year":"1994","unstructured":"Hediger, M.A., and D.B. Rhoads. 1994. Molecular physiology of sodium\u2013glucose cotransporters. Physiological Reviews 74: 993\u20131026.","journal-title":"Physiological Reviews"},{"key":"419_CR24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/330379a0","volume":"330","author":"MA Hediger","year":"1987","unstructured":"Hediger, M.A., M.J. Coady, T.S. Ikeda, and E.M. Wright. 1987. Expression cloning and cDNA sequencing of the Na(+)\/glucose co-transporter. Nature 330: 379\u2013381.","journal-title":"Nature"},{"key":"419_CR25","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1248\/cpb.46.1545","volume":"46","author":"M Hongu","year":"1998","unstructured":"Hongu, M., N. Funami, Y. Takahashi, K. Saito, K. Arakawa, M. Matsumoto, H. Yamakita, and K. Tsujihara. 1998a. Na(+)\u2013glucose cotransporter inhibitors as antidiabetic agents. III. Synthesis and pharmacological properties of 4\u2032-dehydroxyphlorizin derivatives modified at the OH groups of the glucose moiety. Chemical & Pharmaceutical Bulletin (Tokyo) 46: 1545\u20131555.","journal-title":"Chemical & Pharmaceutical Bulletin (Tokyo)"},{"key":"419_CR26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1248\/cpb.46.22","volume":"46","author":"M Hongu","year":"1998","unstructured":"Hongu, M., T. Tanaka, N. Funami, K. Saito, K. Arakawa, M. Matsumoto, and K. Tsujihara. 1998b. Na(+)\u2013glucose cotransporter inhibitors as antidiabetic agents. II. Synthesis and structure-activity relationships of 4\u2032-dehydroxyphlorizin derivatives. Chemical & Pharmaceutical Bulletin (Tokyo) 46: 22\u201333.","journal-title":"Chemical & Pharmaceutical Bulletin (Tokyo)"},{"key":"419_CR27","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/0091270009352185","volume":"50","author":"EK Hussey","year":"2010","unstructured":"Hussey, E.K., R.L. Dobbins, R.R. Stoltz, N.L. Stockman, R.L. O\u2019Connor-Semmes, A. Kapur, S.C. Murray, D. Layko, and D.J. Nunez. 2010. Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: A randomized double-blind study. Journal of Clinical Pharmacology 50: 636\u2013646.","journal-title":"Journal of Clinical Pharmacology"},{"key":"419_CR29","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/nature05482","volume":"444","author":"SE Kahn","year":"2006","unstructured":"Kahn, S.E., R.L. Hull, and K.M. Ulzschneider. 2006. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444: 840\u2013846.","journal-title":"Nature"},{"key":"419_CR30","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","volume":"355","author":"SE Khan","year":"2006","unstructured":"Khan, S.E., S.M. Haffner, M.A. Heise, S.E. Kahn, S.M. Haffner, M.A. Heise, W.H. Herman, R.R. Holman, N.P. Jones, B.G. Kravitz, J.M. Lachin, M.C. O\u2019Neill, B. Zinman, and G. Viberti. 2006. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. The New England Journal of Medicine 355: 2427\u20132443.","journal-title":"The New England Journal of Medicine"},{"key":"419_CR31","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1021\/jf4030739","volume":"62","author":"SJ Kim","year":"2014","unstructured":"Kim, S.J., H.Y. Quan, K.J. Kyong, D.Y. Kim, G.W. Kim, H.K. Jo, and S.H. Chung. 2014. Beneficial effect of betulinic acid on hyperglycemia via suppression of hepatic glucose production. Journal of Agricultural and Food Chemistry 62: 434\u2013442.","journal-title":"Journal of Agricultural and Food Chemistry"},{"key":"419_CR32","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","volume":"85","author":"B Komoroski","year":"2009","unstructured":"Komoroski, B., N. Vachharajani, Y. Feng, L. Li, D. Kornhauser, and M. Pfister. 2009. Dapagliflozin: A novel, selective SGLT2 inhibitor, improved glycemic control over 2\u00a0weeks in patients with type 2 diabetes mellitus. Clinical Pharmacology and Therapeutics 85: 513\u2013519.","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"419_CR33","doi-asserted-by":"crossref","unstructured":"Markham, A., and S. Elkinson. 2014. Luseogliflozin: First global approval. Drugs 74: 945\u2013950.","DOI":"10.1007\/s40265-014-0230-8"},{"key":"419_CR34","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1053\/j.ajkd.2008.12.031","volume":"53","author":"O Marsenic","year":"2009","unstructured":"Marsenic, O. 2009. Glucose control by the kidney: An emerging target in diabetes. American Journal of Kidney Disease 53: 875\u2013883.","journal-title":"American Journal of Kidney Disease"},{"key":"419_CR35","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1053\/meta.2002.34700","volume":"51","author":"M Matsuda","year":"2002","unstructured":"Matsuda, M., R.A. Defronzo, L. Glass, A. Consoil, M. Giordano, P. Bressler, and S. Delprato. 2002. Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. Metabolism 51: 1111\u20131119.","journal-title":"Metabolism"},{"key":"419_CR36","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","volume":"124","author":"A Merovci","year":"2014","unstructured":"Merovci, A., C. Solis-Herrera, G. Daniele, R. Eldor, T.V. Fiorentino, D. Tripathy, J. Xiong, Z. Perez, L. Norton, M.A. Abdul-Ghani, and R.A. DeFronzo. 2014. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. The Journal of Clinical Investigation 124: 509\u2013514.","journal-title":"The Journal of Clinical Investigation"},{"key":"419_CR37","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1124\/dmd.112.049551","volume":"41","author":"Z Miao","year":"2013","unstructured":"Miao, Z., G. Nucci, N. Amin, R. Sharma, V. Mascitti, M. Tugnait, A.D. Vaz, E. Callegari, and A.S. Kalgutkar. 2013. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metabolism and Disposition 41: 445\u2013456.","journal-title":"Drug Metabolism and Disposition"},{"key":"419_CR38","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1007\/s00125-009-1359-y","volume":"52","author":"H Mulder","year":"2009","unstructured":"Mulder, H., C. Nagorny, V. Lyssenko, and L. Groop. 2009. Melatonin receptors in pancreatic islets: Good morning to a novel type 2 diabetes gene. Diabetologia 52: 1240\u20131249.","journal-title":"Diabetologia"},{"key":"419_CR39","first-page":"E414","volume":"304","author":"T Nagata","year":"2012","unstructured":"Nagata, T., M. Fukazawa, K. Honda, T. Yata, M. Kawai, M. Yamane, N. Murao, K. Yamaguchi, M. Kato, T. Mitsui, Y. Suzuki, S. Ikeda, and Y. Kawabe. 2012. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. AJP: Endocrinology and Metabolism 304: E414\u2013E423.","journal-title":"AJP: Endocrinology and Metabolism"},{"key":"419_CR40","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/11318680-000000000-00000","volume":"70","author":"JJ Neumiller","year":"2010","unstructured":"Neumiller, J.J., J.R. White, and R.K. Campbell. 2010. Sodium-glucose co-transporter inhibitors: Progress and therapeutic potential in type 2 diabetes mellitus. Drugs 70: 377\u2013385.","journal-title":"Drugs"},{"key":"419_CR41","doi-asserted-by":"crossref","first-page":"7828","DOI":"10.1021\/jm300884k","volume":"55","author":"Y Ohtake","year":"2012","unstructured":"Ohtake, Y., T. Sato, T. Kobayashi, M. Nishimoto, N. Taka, K. Takano, K. Yamamoto, M. Ohmori, M. Yamaguchi, K. Takami, S.Y. Yeu, K.H. Ahn, H. Matsuoka, K. Morikawa, M. Suzuki, H. Hagita, K. Ozawa, K. Yamaguchi, K. Kato, and S. Ikeda. 2012. Discovery of tofogliflozin, a novel c-arylglucoside with ano-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (sglt2) inhibitor for the treatment of type 2 diabetes. Journal of Medicinal Chemistry 55: 7828\u20137840.","journal-title":"Journal of Medicinal Chemistry"},{"key":"419_CR42","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40265-014-0204-x","volume":"74","author":"RM Poole","year":"2014","unstructured":"Poole, R.M., and R.T. Dungo. 2014. Ipragliflozin: First global approval. Drugs 74: 611\u2013617.","journal-title":"Drugs"},{"key":"419_CR43","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","volume":"54","author":"H Rahmoune","year":"2005","unstructured":"Rahmoune, H., P.W. Thompson, J.M. Ward, C.D. Smith, G. Hong, and J. Brown. 2005. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54: 3427\u20133434.","journal-title":"Diabetes"},{"key":"419_CR44","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","volume":"37","author":"GM Reaven","year":"1988","unstructured":"Reaven, G.M. 1988. Role of insulin resistance in human disease. Diabetes 37: 1595\u20131607.","journal-title":"Diabetes"},{"key":"419_CR45","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1463-1326.2011.01406.x","volume":"13","author":"S Sha","year":"2011","unstructured":"Sha, S., D. Devineni, A. Ghosh, D. Polidori, S. Chien, D. Wexler, K. Shalayda, K. Demarest, and P. Rothenberg. 2011. Canagliflozin: A novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes, Obesity & Metabolism 13: 669\u2013672.","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"419_CR46","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","volume":"15","author":"K Stenl\u00f6f","year":"2013","unstructured":"Stenl\u00f6f, K., W.T. Cefalu, K.A. Kim, M. Alba, K. Usiskin, C. Tong, W. Canovatchel, and G. Meininger. 2013. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes, Obesity & Metabolism 15: 372\u2013382.","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"419_CR47","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/S0140-6736(05)61032-X","volume":"365","author":"M Stumvoll","year":"2005","unstructured":"Stumvoll, M., B.J. Goldstein, and T.W. van Haeften. 2005. Type 2 diabetes: Principles of pathogenesis and therapy. Lancet 365: 1333\u20131346.","journal-title":"Lancet"},{"key":"419_CR48","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1248\/cpb.44.1174","volume":"44","author":"K Tsujihara","year":"1996","unstructured":"Tsujihara, K., M. Hongu, K. Saito, M. Inamasu, K. Arakawa, A. Oku, and M. Matsumoto. 1996. Na(+)\u2013glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4\u2032-dehydroxyphlorizin derivatives based on a new concept. Chemical & Pharmaceutical Bulletin (Tokyo) 44: 1174\u20131180.","journal-title":"Chemical & Pharmaceutical Bulletin (Tokyo)"},{"key":"419_CR49","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s00424-003-1085-0","volume":"447","author":"M Uldry","year":"2004","unstructured":"Uldry, M., and B. Thorens. 2004. The SLC2 family of facilitated hexose and polyol transporters. Pfl\u00fcgers Archiv 447: 480\u2013489.","journal-title":"Pfl\u00fcgers Archiv"},{"key":"419_CR50","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.2337\/dc09-0517","volume":"32","author":"JP Wilding","year":"2009","unstructured":"Wilding, J.P., P. Norwood, C. T\u2019joen, A. Bastien, J.F. List, and F.T. Fiedorek. 2009. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: Applicability of a novel insulin-independent treatment. Diabetes Care 32: 1656\u20131662.","journal-title":"Diabetes Care"},{"key":"419_CR51","doi-asserted-by":"crossref","first-page":"F10","DOI":"10.1152\/ajpcell.2001.280.5.C1262","volume":"280","author":"EM Wright","year":"2001","unstructured":"Wright, E.M. 2001. Renal Na(+)\u2013glucose cotransporters. American Journal of Physiology: Renal Physiology 280: F10\u2013F18.","journal-title":"American Journal of Physiology: Renal Physiology"},{"key":"419_CR52","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","volume":"91","author":"EM Wright","year":"2011","unstructured":"Wright, E.M., D.D. Loo, and B.A. Hirayama. 2011. Biology of human sodium glucose transporters. Physiological Reviews 91: 733\u2013794.","journal-title":"Physiological Reviews"},{"key":"419_CR53","first-page":"53","volume":"25","author":"HD Yuan","year":"2010","unstructured":"Yuan, H.D., and S.H. Chung. 2010. Protective effects of fermented ginseng on streptozotocin-induced pancreatic \u03b2-cell damage through inhibition of NF-\u03baB. International Journal of Molecular Medicine 25: 53\u201358.","journal-title":"International Journal of Molecular Medicine"},{"key":"419_CR54","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/clpt.2012.58","volume":"92","author":"B Zambrowicz","year":"2012","unstructured":"Zambrowicz, B., J. Freiman, P.M. Brown, K.S. Frazier, A. Turnage, J. Bronner, D. Ruff, M. Shadoan, P. Banks, F. Mseeh, D.B. Rawlins, N.C. Goodwin, R. Mabon, B.A. Harrison, A. Wilson, A. Sands, and D.R. Powell. 2012. LX4211, a dual SGLT1\/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clinical Pharmacology and Therapeutics 92: 158\u2013169.","journal-title":"Clinical Pharmacology and Therapeutics"}],"container-title":["Archives of Pharmacal Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-014-0419-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12272-014-0419-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12272-014-0419-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T15:10:46Z","timestamp":1565536246000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12272-014-0419-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,21]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["419"],"URL":"https:\/\/doi.org\/10.1007\/s12272-014-0419-0","relation":{},"ISSN":["0253-6269","1976-3786"],"issn-type":[{"value":"0253-6269","type":"print"},{"value":"1976-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,21]]}}}